TechnicalOpinion

Advantage of Microdosing GLPs

Andrew Huberman

GLP-1 medications should be treated as lifelong therapies rather than stopped abruptly. Microdosing offers a sustainable alternative that maintains weight loss while reducing medication dosage. Cycling on and off GLP-1s causes progressive body composition deterioration through repeated loss of lean mass and regain of fat mass.

Summary

The transcript discusses the challenges of discontinuing GLP-1 medications and proposes microdosing as a sustainable long-term strategy. The speaker emphasizes that GLP-1s are designed to be continuous therapies rather than temporary treatments. When patients attempt to stop these medications, they face significant complications, primarily related to weight regain. The key problem with stopping GLP-1s is the unfavorable shift in body composition that occurs. When weight loss occurs on GLP-1s like semaglutide, approximately one-third of the lost weight consists of lean mass (primarily muscle with some bone loss). When patients discontinue the medication and regain weight, they regain primarily fat rather than the lost lean mass. This creates a problematic cycle: each time patients cycle on and off the medication, they lose some muscle but regain fat, progressively worsening their overall body composition with each cycle. To prevent this deterioration, the speaker recommends either adopting a microdosing approach—where patients take lower maintenance doses to keep weight stable while feeling good—or implementing a bridging plan that transitions to an alternative procedure or intervention to maintain weight loss without continued cycling. The core argument is that continuous or microdosed therapy prevents the destructive body composition shifts that occur with repeated on-off cycles.

Key Insights

  • The speaker claims that approximately one-third of weight lost on GLP-1s like semaglutide is lean mass (muscle and bone), not fat.
  • The speaker argues that when patients regain weight after stopping GLP-1s, they regain primarily fat rather than the lost lean mass, creating unfavorable body composition shifts.
  • The speaker contends that repeated cycling on and off GLP-1s progressively worsens body composition with each cycle due to cumulative lean mass loss and fat regain.
  • The speaker proposes that GLP-1 medications should be treated as lifelong medicines rather than temporary treatments to be stopped.
  • The speaker recommends microdosing or bridging to alternative procedures as strategies to maintain weight loss while avoiding the destructive effects of cycling on and off medication.

Topics

GLP-1 medications as lifelong therapyBody composition changes during weight lossLean mass loss on GLP-1sMicrodosing as maintenance strategyCycling on and off medication effects

Transcript

[0:00] If you stop the GLP-1s, there's problems, right? This is not meant to be stopped. These are kind of lifelong medicines. Instead of stopping it, just go to microdosing. And you'll find a spot, hopefully, you know, not everyone does, but you'll find a spot where you keep the weight off, you feel good, and you're not taking as much of the med. Now, the problem with coming off of them is, especially with the original drugs, you know, like semaglutide's an example, right, where when you lose weight, about 1/3 of the weight you lose would be lean mass, so most muscle, right, maybe some bone, et cetera. [0:32] And the problem is when you cycle on and…

Full transcript available for MurmurCast members

Sign Up to Access

More from Andrew Huberman

Get AI summaries like this delivered to your inbox daily

Get AI summaries delivered to your inbox

MurmurCast summarizes your YouTube channels, podcasts, and newsletters into one daily email digest.